Page 90 - Drug Class Review
P. 90
Page 75 of 205
Drug Effectiveness Review Project
placebo 76.3 64 4% 90% 2% 2% 2% 18.08
galantamine 76.5 64 4% 90% 2% 2% 3% 17.8 Primary Outcome Measures: ADAS-cog/11 score; CIBIC-plus score Timing of assessments: Screening, baseline, and weeks 4,8,12, and 26 Both galantamine treatments were significantly more effective than placebo as measured by the ADAS-cog/11 score (P < 0.001 galantamine PRC, P < 0.01 for galantamine) No statistically significant differences were observed between active treatments and placebo on Both galantamine treatments were significantly more effective than placebo in ADCS-ADL measure (P < 0.001 galantamine PRC, P = 0.
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes
galantamine PRC 76.6 64 3% 93% 1% 3% 1% 17.96 Secondary Outcome Measures: ADCS-ADL; NPI Health Outcome Measures: the CIBIC-plus scale on the NPI measure Intermediate Outcome Measures: N/A
• • • • •
Final Report Update 1 Authors: Brodaty et al. Year: 2005 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Black: White: Hispanic: Asian: Other: Other germane population qualities: MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
